TiO2 photocatalytic degradation and transformation of oxazaphosphorine drugs in an aqueous environment

被引:53
作者
Lai, Webber Wei-Po [1 ]
Lin, Hank Hui-Hsiang [1 ]
Lin, Angela Yu-Chen [1 ]
机构
[1] Natl Taiwan Univ, Grad Inst Environm Engn, Taipei 106, Taiwan
关键词
Photocatalytic degradation; Titanium dioxide; Oxazaphosphorine drugs; Toxicity; SOLID-PHASE EXTRACTION; WASTE-WATER; CYTOSTATIC DRUGS; ORAL TROFOSFAMIDE; ORGANIC-MATTER; CLOFIBRIC ACID; CYCLOPHOSPHAMIDE; IFOSFAMIDE; PHARMACEUTICALS; METABOLITES;
D O I
10.1016/j.jhazmat.2015.01.045
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
This study investigated the TiO2 photocatalytic degradation and transformation of the oxazaphosphorines ifosfamide (IFO), cyclophosphamide (CP) and trofosfamide (TRO). Under the optimum conditions of TiO2 = 100 mg/L, IFO = 100 mu g/L and solution pH = 5.5, IFO was completely removed within 10 min (k = 0.433 min(-1)). The results indicated that (OHfree)-O-center dot radicals generated by valence holes in the bulk solution were the predominant species for the degradation of IFO. At higher initial concentrations of oxazaphosphorines (20 mg/L), >50% of TOC remained after 6 h of reaction time, indicating that parent compounds were transformed to byproducts, which exhibit higher Microtox acute toxicities; chlorinated byproducts were likely the source of toxicity. Photocatalytic degradation pathways of the three oxazaphosphorines were proposed. IFO, CP and TRO follow very similar pathways and bond-breaking processes: ketonization and breaking of the C-CI bond, the P-N bond and the C-N bond (N-dechloroethylation). Chloride (Cl-) release is likely the first and primary step in the decomposition process. Several of the identified byproducts were also metabolites, which implies that photocatalytic oxidation proceeds through pathways that are similar to metabolic pathways. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 62 条
[11]   PHOTOCATALYTIC OXIDATION OF ORGANIC-ACIDS ON QUANTUM-SIZED SEMICONDUCTOR COLLOIDS [J].
CARRAWAY, ER ;
HOFFMAN, AJ ;
HOFFMANN, MR .
ENVIRONMENTAL SCIENCE & TECHNOLOGY, 1994, 28 (05) :786-793
[12]   Role of primary active species and TiO2 surface characteristic in UV-illuminated photodegradation of Acid Orange 7 [J].
Chen, YX ;
Yang, SY ;
Wang, K ;
Lou, LP .
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY, 2005, 172 (01) :47-54
[13]   Heterogeneous photocatalytic treatment of pharmaceutical micropollutants: Effects of wastewater effluent matrix and catalyst modifications [J].
Choi, Jihyun ;
Lee, Hongshin ;
Choi, Yeoseon ;
Kim, Soonhyun ;
Lee, Seokheon ;
Lee, Seunghak ;
Choi, Wonyong ;
Lee, Jaesang .
APPLIED CATALYSIS B-ENVIRONMENTAL, 2014, 147 :8-16
[14]   Recent developments in photocatalytic water treatment technology: A review [J].
Chong, Meng Nan ;
Jin, Bo ;
Chow, Christopher W. K. ;
Saint, Chris .
WATER RESEARCH, 2010, 44 (10) :2997-3027
[15]   Removing pharmaceuticals and endocrine-disrupting compounds from wastewater by photocatalysis [J].
Dalrymple, Omatoyo K. ;
Yeh, Daniel H. ;
Trotz, Maya A. .
JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY, 2007, 82 (02) :121-134
[16]   MONITORING EXPOSURE OF HOSPITAL PERSONNEL HANDLING CYTOSTATIC DRUGS AND CONTAMINATED MATERIALS [J].
DEMEO, MP ;
MERONO, S ;
DEBAILLE, AD ;
BOTTA, A ;
LAGET, M ;
GUIRAUD, H ;
DUMENIL, G .
INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, 1995, 66 (06) :363-368
[17]   Photocatalytic degradation of carbamazepine, clofibric acid and iomeprol with P25 and Hombikat UV100 in the presence of natural organic matter (NOM) and other organic water constituents [J].
Doll, TE ;
Frimmel, FH .
WATER RESEARCH, 2005, 39 (2-3) :403-411
[18]   Kinetic study of photocatalytic degradation of carbamazepine, clofibric acid, iomeprol and iopromide assisted by different TiO2 materials -: determination of intermediates and reaction pathways [J].
Doll, TE ;
Frimmel, FH .
WATER RESEARCH, 2004, 38 (04) :955-964
[19]   Investigation of retardation effects on the titanium dioxide photodegradation system [J].
Epling, GA ;
Lin, C .
CHEMOSPHERE, 2002, 46 (06) :937-944
[20]  
Fleming RA, 1997, PHARMACOTHERAPY, V17, pS146